Stone by stone, building by building, the broad swath of Hudson riverfront land that was once a GM assembly plant is filling ...

Regeneron Pharmaceuticals was outbid in its effort to buy 23andMe by a nonprofit led by the bankrupt genetics testing company’s co-founder. California-based TTAM Research Institute, led by Anne ...

Financial giants have made a conspicuous bearish move on Regeneron Pharmaceuticals. Our analysis of options history for Regeneron Pharmaceuticals REGN revealed 43 unusual trades. Delving into the ...

Regeneron Pharmaceuticals recently announced a strategic in-licensing agreement with Hansoh Pharmaceuticals, acquiring rights for a dual GLP-1/GIP receptor agonist, HS-20094. Concurrently ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on Monday that its experimental drug, when combined with Novo Nordisk’s popular obesity medication Wegovy, helped patients preserve up to ...

Regeneron Pharmaceuticals announced favorable Phase 3 trial results for itepekimab and entered a significant licensing agreement with Telesis Bio, enhancing its R&D capabilities. Despite these ...

In the latest quarter, 21 analysts provided ratings for Regeneron Pharmaceuticals REGN, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ...

Regeneron Pharmaceuticals (NASDAQ:REGN) shares experienced a significant 19% drop on Friday, May 30, following the unexpected failure of itepekimab, its chronic obstructive pulmonary disease (COPD ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other Friday’s worst performers. Regeneron Pharmaceuticals fell by 19.01 ...

As of January 28, 2025, the average one-year price target for Regeneron Pharmaceuticals is $1,022.63/share. The forecasts range from a low of $570.65 to a high of $1,291.50.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...